Where Will Eli Lilly Be in 1 Year?
Pharmaceutical powerhouse Eli Lilly (NYSE: LLY) had a banner year in 2024. The company's sales surged 32% to over $45 billion ...
Eli Lilly Vs. Hims & Hers In DTC Weight Loss Market? - There Is Only One Winner
Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.
Eli Lilly (NYSE:LLY) Unveils Positive Phase 2 Results For Heart Disease Therapy Amid 5% Share Dip
Eli Lilly (NYSE:LLY) experienced a 6% increase in price over the last quarter, coinciding with several major developments.
Eli Lilly will soon release key data on its weight loss pill. Here's why it could be a game-changer
The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...
Why Novo Nordisk Stock Dropped on Monday, but Eli Lilly and Him & Hers Health Popped
First, Novo Nordisk is expanding its program to sell Wegovy GLP-1 weight loss drugs at discounted prices. Second, Novo is ...
TD Cowen Sticks to Its Buy Rating for Eli Lilly & Co (LLY)
In a report released today, Steve Scala from TD Cowen maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price ...
Morningstar2d
Eli Lilly and Co
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Hims & Hers to sell Lilly’s Zepbound
Hims shares gained as much as 14% in New York, their biggest gain since Feb. 19.
CNBCTV1810d
Eli Lilly’s Mounjaro targets India’s $150 billion weight-loss market amid rising diabetes crisis
Eli Lilly launches Mounjaro in India, targeting the $150B weight-loss market. The GLP-1 drug offers diabetes control & major ...